Newsletters

[Blood] Investigators identified fibroblast‑derived fibroblast growth factor 18 (FGF18) as a novel stromal cytokine that reprograms leukemia-immune interactions.

[Blood] Researchers identified JUND as a driver of resistance to menin–MLL inhibitors in MLL-rearranged leukemia, revealing a promising combination strategy to improve therapeutic responses.

[Leukemia] Scientists showed that local oxygen levels regulate hematopoietic stem cell growth and potency, identifying oxygen-sensing pathways and PRSS2 as potential targets to improve blood stem cell therapies.

[Communications Biology] Using a leukemia suppression model and CRISPR screening, the authors found that the choline transporter SLC44A1 is overexpressed in leukemia patients and impacts leukemogenesis.

[Environmental Toxicology and Pharmacology] Using human iPSCs, investigators examined how sodium arsenite affects the formation of hematopoietic stem and progenitor cells, which are essential for lifelong blood production.

[Signal Transduction and Targeted Therapy] Scientists demonstrated that orelabrutinib significantly improves progression-free survival and response rates over chemoimmunotherapy as a first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma.

[Leukemia] This phase I clinical trial evaluated CD7-targeted CAR-T cell therapy in patients with relapsed/refractory CD7-positive AML. Patients received a single infusion of autologous or donor-derived CD7 CAR-T cells using a standard 3 + 3 dose escalation design across two dose levels

[Cancer Science] The authors highlight how splicing factor mutations shape clonal hematopoiesis and drive progression toward myeloid neoplasms, revealing age-dependent mechanisms of clonal expansion and leukemogenesis.

[The European Research Council] The European Research Council (ERC) has announced the names of its grantees to be awarded the Proof of Concept Grants. Funding for this first round of 2026, worth €27.3 million, will go to 182 researchers.

[Orca Bio] Orca Bio announced FDA approval of TREGZI™ (Orca-T^®), a precision-engineered cell therapy for matched-donor hematopoietic stem cell transplantation in adults with hematologic malignancies, designed to improve chronic graft-versus-host disease-free survival.

[Nature Communications] The authors examined whether the inhibitory postsynaptic scaffold protein Gephyrin mediates selective myelination of specific axon classes in the larval zebrafish.

[Nature Aging] Investigators showed that the conserved α-helical region spanning residues 320–340 is a therapeutically actionable target for TAR DNA-binding protein 43 (TDP-43) neurotoxicity.